Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 5/2019

01-10-2019 | Hyperparathyroidism | Review

The role of uric acid in mineral bone disorders in chronic kidney disease

Authors: Baris Afsar, Alan A. Sag, Cinar Oztosun, Masanari Kuwabara, Mario Cozzolino, Adrian Covic, Mehmet Kanbay

Published in: Journal of Nephrology | Issue 5/2019

Login to get access

Abstract

Increasing survival in the chronic kidney disease (CKD) population exposes the bone to the cumulative detrimental sequelae of CKD, now defined physiologically and histopathologically as chronic kidney disease mineral bone disorder (CKD-BMD). This disorder is increasingly recognized as a “nontraditional” driver of morbidity and mortality and presents an opportunity to improve CKD outcomes via research. However, recent advances in the literature on this topic have not yet been collected into a single review. Therefore, this report aims to discuss the disordered renal-bone axis in CKD-BMD, molecular and hormonal drivers, novel treatment strategies, and forthcoming research in a clinician-directed format. A key novel topic will be the unique impact of uric acid on CKD-BMD, which is poised to apply extensive existing research in the uric acid domain to benefit the CKD-BMD population.
Literature
1.
Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL et al (2010) Vascular calcification in chronic kidney disease. Clin Sci (Lond). 119(3):111–121CrossRefPubMed
2.
Sag AA, Covic A, London G, Vervloet M, Goldsmith D, Gorriz JL et al (2016) Clinical imaging of vascular disease in chronic kidney disease. Int Urol Nephrol 48(6):827–837CrossRefPubMed
3.
Kanbay M, Goldsmith D, Akcay A, Covic A (2009) Phosphate—the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 27(2):220–230CrossRefPubMed
4.
5.
Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B et al (2010) Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 5(10):1780–1786CrossRefPubMedPubMedCentral
6.
Kanbay M, Vervloet M, Cozzolino M, Siriopol D, Covic A, Goldsmith D et al (2017) Novel Faces of Fibroblast Growth Factor 23 (FGF23): iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. Calcif Tissue Int 100(3):217–228CrossRefPubMed
7.
Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D et al (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029–2042CrossRefPubMed
8.
Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H et al (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99(10):E1854–E1861CrossRefPubMed
9.
Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease—mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone 100:80–86CrossRefPubMedPubMedCentral
10.
Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA (2017) Serum uric acid and acute kidney injury: a mini review. J Adv Res. 8(5):529–536CrossRefPubMed
11.
Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA et al (2018) Increased serum uric acid over five years is a risk factor for developing fatty liver. Sci Rep. 8(1):11735CrossRefPubMedPubMedCentral
12.
Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C et al (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med. 29:3–8CrossRefPubMed
13.
Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A et al (2015) Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med 63(8):924–929CrossRefPubMed
14.
Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E et al (2011) Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 33(4):298–304CrossRefPubMedPubMedCentral
15.
Kanbay M, Siriopol D, Nistor I, Elcioglu OC, Telci O, Takir M et al (2014) Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol 39(4):348–356CrossRefPubMed
16.
Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A (2010) Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif 30(4):288–295CrossRefPubMed
17.
Toyama T, Furuichi K, Shimizu M, Hara A, Iwata Y, Sakai N et al (2015) Relationship between serum uric acid levels and chronic kidney disease in a japanese cohort with normal or mildly reduced kidney function. PLoS One 10(9):e0137449CrossRefPubMedPubMedCentral
18.
Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E et al (2012) Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 36(4):324–331CrossRefPubMed
19.
Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, Armutcu F et al (2011) Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 33(4):325–331CrossRefPubMedPubMedCentral
20.
von Lueder TG, Girerd N, Atar D, Agewall S, Lamiral Z, Kanbay M et al (2015) Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the high-risk myocardial infarction database initiative. Eur J Heart Fail 17(11):1144–1151CrossRef
21.
Turak O, Ozcan F, Tok D, Isleyen A, Sokmen E, Tasoglu I et al (2013) Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens (Greenwich). 15(1):7–13CrossRef
22.
Cagli K, Turak O, Canpolat U, Ozcan F, Tok D, Mendi MA et al (2015) Association of serum uric acid level with blood pressure variability in newly diagnosed essential hypertension. J Clin Hypertens (Greenwich). 17(12):929–935CrossRefPubMedCentral
23.
Kuwabara M, Kanbay M, Hisatome I (2018) Uric acid and hypertension because of arterial stiffness. Hypertension 72(3):582–584CrossRefPubMed
24.
Lundquist AL, Nigwekar SU (2016) Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens 25(2):120–126CrossRefPubMedPubMedCentral
25.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31–38CrossRefPubMed
26.
Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79(12):1370–1378CrossRefPubMedPubMedCentral
27.
Farrow EG, Davis SI, Summers LJ, White KE (2009) Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20(5):955–960CrossRefPubMedPubMedCentral
28.
29.
Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D et al (2017) The role of phosphate in kidney disease. Nat Rev Nephrol. 13(1):27–38CrossRefPubMed
30.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 69(11):1945–1953CrossRefPubMed
31.
32.
Ferreira A, Drueke TB (2000) Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci 320(2):85–89CrossRefPubMed
33.
Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D’Avino R Jr et al (2018) CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. Atherosclerosis. 278:49–59CrossRefPubMed
34.
Kanbay M, Afsar B, Gusbeth-Tatomir P, Covic A (2010) Arterial stiffness in dialysis patients: where are we now? Int Urol Nephrol 42(3):741–752CrossRefPubMed
35.
36.
Peng H, Li H, Li C, Chao X, Zhang Q, Zhang Y (2013) Association between vitamin D insufficiency and elevated serum uric acid among middle-aged and elderly Chinese Han women. PLoS One 8(4):e61159CrossRefPubMedPubMedCentral
37.
Yilmaz H, Kaya M, Sahin M, Delibasi T (2012) Is vitamin D status a predictor glycaemic regulation and cardiac complication in type 2 diabetes mellitus patients? Diabetes Metab Syndr. 6(1):28–31CrossRefPubMed
38.
Vanholder R, Patel S, Hsu CH (1993) Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 4(4):1035–1038PubMed
39.
Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Yamakita J, Higashino K (1998) Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. Metabolism. 47(3):336–338CrossRefPubMed
40.
Hsu CH, Patel SR, Young EW, Vanholder R (1991) Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 260(4 Pt 2):F596–F601PubMed
41.
Chen W, Roncal-Jimenez C, Lanaspa M, Gerard S, Chonchol M, Johnson RJ et al (2014) Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism. 63(1):150–160CrossRefPubMed
42.
Thakkinstian A, Anothaisintawee T, Chailurkit L, Ratanachaiwong W, Yamwong S, Sritara P et al (2015) Potential causal associations between vitamin D and uric acid: bidirectional mediation analysis. Sci Rep. 5:14528CrossRefPubMedPubMedCentral
43.
44.
Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK (2012) The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther. 14(2):R56CrossRefPubMedPubMedCentral
45.
Alemzadeh R, Kichler J (2016) Uric acid-induced inflammation is mediated by the parathyroid hormone: 25-hydroxyvitamin D ratio in obese adolescents. Metab Syndr Relat Disord. 14(3):167–174CrossRefPubMed
46.
Saleh F, Jorde R, Sundsfjord J, Haug E, Figenschau Y (2006) Causes of secondary hyperparathyroidism in a healthy population: the Tromso study. J Bone Miner Metab 24(1):58–64CrossRefPubMed
47.
Hisatome I, Ishimura M, Sasaki N, Yamakawa M, Kosaka H, Tanaka Y et al (1992) Renal handling of urate in two patients with hyperuricemia and primary hyperparathyroidism. Intern Med 31(6):807–811CrossRefPubMed
48.
Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A (2001) Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf) 54(6):805–811CrossRef
49.
Bergenfelz A, Bladstrom A, Their M, Nordenstrom E, Valdemarsson S, Westerdahl J (2007) Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J Surg. 31(7):1393–1400 (discussion 401-2) CrossRefPubMed
50.
Valdemarsson S, Lindblom P, Bergenfelz A (1998) Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med 244(3):241–249CrossRefPubMed
51.
Christensson T (1977) Serum urate in subjects with hypercalcaemic hyperparathyroidism. Clin Chim Acta 80(3):529–533CrossRefPubMed
52.
Dalbeth N, Horne A, Gamble GD, Ames R, Mason B, McQueen FM et al (2009) The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. Rheumatology (Oxford) 48(2):195–197CrossRef
53.
Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59–68CrossRefPubMed
54.
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429–435CrossRefPubMed
55.
Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64(6):2272–2279CrossRefPubMed
56.
Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 205(2):385–390CrossRefPubMed
57.
Sakoh T, Nakayama M, Tsuchihashi T, Yoshitomi R, Tanaka S, Katafuchi E et al (2016) Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease. Metabolism. 65(10):1498–1507CrossRefPubMed
58.
Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener C (2014) Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients. Transplant Proc. 46(1):180–183CrossRefPubMed
59.
Gutierrez OM, Wolf M, Taylor EN (2011) Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 6(12):2871–2878CrossRefPubMedPubMedCentral
60.
Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21(9):1427–1435CrossRefPubMed
61.
Andres M, Quintanilla MA, Sivera F, Sanchez-Paya J, Pascual E, Vela P et al (2016) Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheumatol. 68(6):1531–1539CrossRefPubMed
62.
Kim H, Kim SH, Choi AR, Kim S, Choi HY, Kim HJ et al (2017) Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study. Medicine (Baltimore). 96(14):e6565CrossRefPubMedPubMedCentral
63.
Mehta T, Nuccio E, McFann K, Madero M, Sarnak MJ, Jalal D (2015) Association of uric acid with vascular stiffness in the framingham heart study. Am J Hypertens 28(7):877–883CrossRefPubMed
64.
Lee CT, Chua S, Hsu CY, Tsai YC, Ng HY, Kuo CC et al (2013) Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers 34(4):229–235CrossRefPubMedPubMedCentral
65.
Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M et al (2018) Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post hoc analysis of a randomized clinical trial. PLoS One 13(10):e0205831CrossRefPubMedPubMedCentral
66.
Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N et al (2007) Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39(4):1227–1233CrossRefPubMed
67.
Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393CrossRefPubMedPubMedCentral
68.
Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al (2011) A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6(8):1887–1894CrossRefPubMedPubMedCentral
69.
Nabipour I, Sambrook PN, Blyth FM, Janu MR, Waite LM, Naganathan V et al (2011) Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res 26(5):955–964CrossRefPubMed
70.
Ahn SH, Lee SH, Kim BJ, Lim KH, Bae SJ, Kim EH et al (2013) Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int 24(12):2961–2970CrossRefPubMed
71.
Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y (2009) Oxidative stress in bone remodelling and disease. Trends Mol Med. 15(10):468–477CrossRefPubMed
72.
Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS et al (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106(3):852–859CrossRefPubMed
73.
Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P et al (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88(4):1523–1527CrossRefPubMed
74.
Makovey J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ et al (2013) Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 52(1):400–406CrossRefPubMed
75.
Kim BJ, Baek S, Ahn SH, Kim SH, Jo MW, Bae SJ et al (2014) Higher serum uric acid as a protective factor against incident osteoporotic fractures in Korean men: a longitudinal study using the National Claim Registry. Osteoporos Int 25(7):1837–1844CrossRefPubMed
76.
Zhao DD, Jiao PL, Yu JJ, Wang XJ, Zhao L, Xuan Y et al (2016) Higher serum uric acid is associated with higher bone mineral density in Chinese men with type 2 diabetes mellitus. Int J Endocrinol. 2016:2528956CrossRefPubMedPubMedCentral
77.
Chen Z, Ding Z, Fu C, Yu C, Ma G (2014) Correlation between serum uric Acid and renal function in patients with stable coronary artery disease and type 2 diabetes. J Clin Med Res. 6(6):443–450PubMedPubMedCentral
78.
Kamei K, Konta T, Hirayama A, Suzuki K, Ichikawa K, Fujimoto S et al (2014) A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant 29(12):2286–2292CrossRefPubMed
79.
Malmgren L, McGuigan F, Christensson A, Akesson KE (2017) Reduced kidney function is associated with BMD, bone loss and markers of mineral homeostasis in older women: a 10-year longitudinal study. Osteoporos Int 28(12):3463–3473CrossRefPubMedPubMedCentral
80.
Zhang D, Bobulescu IA, Maalouf NM, Adams-Huet B, Poindexter J, Park S et al (2015) Relationship between serum uric Acid and bone mineral density in the general population and in rats with experimental hyperuricemia. J Bone Miner Res 30(6):992–999CrossRefPubMed
81.
Nybo M, Jespersen B, Aarup M, Ejersted C, Hermann AP, Brixen K (2013) Determinants of bone mineral density in patients on haemodialysis or peritoneal dialysis—a cross-sectional, longitudinal study. Biochem Med (Zagreb). 23(3):342–350CrossRefPubMedPubMedCentral
82.
Denburg MR, Tsampalieros AK, de Boer IH, Shults J, Kalkwarf HJ, Zemel BS et al (2013) Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. J Clin Endocrinol Metab 98(5):1930–1938CrossRefPubMedPubMedCentral
83.
Park SH, Jia T, Qureshi AR, Barany P, Heimburger O, Larsson TE et al (2013) Determinants and survival implications of low bone mineral density in end-stage renal disease patients. J Nephrol. 26(3):485–494CrossRefPubMed
84.
Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A. Potential dangers of serum urate-lowering therapy. Am J Med. 2019
85.
Barreto FC, Costa C, Reis LMD, Custodio MR. Bone biopsy in nephrology practice. J Bras Nefrol. 2018
86.
Cheng Q, Wu X, Du Y, Hong W, Tang W, Li H et al (2018) Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol. Clin Interv Aging 13:2367–2374CrossRefPubMedPubMedCentral
87.
88.
Grieco GE, Cataldo D, Ceccarelli E, Nigi L, Catalano G, Brusco N et al (2018) Serum levels of miR-148a and miR-21-5p are increased in Type 1 diabetic patients and correlated with markers of bone strength and metabolism. Noncoding RNA. 4(4):37PubMedCentral
89.
Yao CJ, Lv Y, Zhang CJ, Jin JX, Xu LH, Jiang J et al (2018) MicroRNA-185 inhibits the growth and proliferation of osteoblasts in fracture healing by targeting PTH gene through down-regulating Wnt/beta-catenin axis: in an animal experiment. Biochem Biophys Res Commun 501(1):55–63CrossRefPubMed
90.
Shilo V, Mor-Yosef Levi I, Abel R, Mihailovic A, Wasserman G, Naveh-Many T et al (2017) Let-7 and MicroRNA-148 regulate parathyroid hormone levels in secondary hyperparathyroidism. J Am Soc Nephrol 28(8):2353–2363CrossRefPubMedPubMedCentral
91.
Jeong S, Oh JM, Oh KH, Kim IW (2017) Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients. PLoS One 12(2):e0170535CrossRefPubMedPubMedCentral
92.
Shao Y, Ren H, Lv C, Ma X, Wu C, Wang Q (2017) Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine 55(1):130–138CrossRefPubMed
93.
Tang ZM, Fang M, Wang JP, Cai PC, Wang P, Hu LH (2014) Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients. J Clin Lab Anal 28(6):446–451CrossRefPubMedPubMedCentral
94.
Hong Q, Yu S, Geng X, Duan L, Zheng W, Fan M et al (2015) High concentrations of uric acid inhibit endothelial cell migration via miR-663 which regulates phosphatase and tensin homolog by targeting transforming growth factor-beta1. Microcirculation. 22(4):306–314CrossRefPubMed
95.
Yu S, Hong Q, Wang Y, Hou K, Wang L, Zhang Y et al (2015) High concentrations of uric acid inhibit angiogenesis via regulation of the Kruppel-like factor 2-vascular endothelial growth factor-A axis by miR-92a. Circ J 79(11):2487–2498CrossRefPubMed
96.
Evenepoel P, D’Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235–240CrossRefPubMed
97.
Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC et al (2014) CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 25(8):1760–1773CrossRefPubMedPubMedCentral
98.
Sugatani T, Agapova OA, Fang Y, Berman AG, Wallace JM, Malluche HH et al (2017) Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int 91(1):86–95CrossRefPubMed
99.
Sugatani T (2018) Systemic activation of activin a signaling causes chronic kidney disease-mineral bone disorder. Int J Mol Sci. 19(9):2490CrossRefPubMedCentral
100.
Peng LN, Chou MY, Liang CK, Lee WJ, Kojima T, Lin MH et al (2018) Association between serum activin A and metabolic syndrome in older adults: potential of activin A as a biomarker of cardiometabolic disease. Exp Gerontol 111:197–202CrossRefPubMed
Metadata
Title
The role of uric acid in mineral bone disorders in chronic kidney disease
Authors
Baris Afsar
Alan A. Sag
Cinar Oztosun
Masanari Kuwabara
Mario Cozzolino
Adrian Covic
Mehmet Kanbay
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2019
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-019-00615-0

Other articles of this Issue 5/2019

Journal of Nephrology 5/2019 Go to the issue

Original Article

Role of anemia and proteinuria in the development of subsequent renal function deterioration in a general population with preserved glomerular filtration rate: a community-based cohort study

Original Article

Catheter-related infections in peritoneal dialysis: comparison of a single center results and the literature data

Review

Anticoagulation in CKD and ESRD

Original Article

Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis

Original Article

The relationship between the concentration of plasma homocysteine and chronic kidney disease: a cross sectional study of a large cohort

Original Article

Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits